so many exclamations!!!!! sign of panic?? most here have been adding to this one my friend so dont worry. If it goes down so be it. everytime it goes down you just keep buying.
you should hear his voice at the investor conferences
boring scientific jargon
there are probably two people in the audience that know what he is saying
uses the same charts and drone everytime
would be nice if he spoke in terminology that simple investors could comprehend
I am not knocking his science or knowledge just his communication skills
better if he was using - Curis investing for Dummies
Maybe a brilliant doctor and a bad investor?
Most Drs are bad CEO's and are replaced once it comes time to marketing a block buster drug
Every point you have referenced should be very positive for increasing the share price, but it hasn't.
No doubt there is price manipulation at times however, the trend for CRIS share price is down and you can only blame so much on manipulation.
The down trend in the overall markets has little effect on clinical stage bio's unless they are on a major index, which is not the case here which is evident by comparing the moves in the index and individual stock price.
Management and success moves the needle to the green. Neither are working here thus the reason for the current share price. That may change in s few years but, not now.
As I see it all Erivedge revenues for next two years will go towards paying note, and it is not clear those revenues will be enough to meet its quarterly obligations. Roche should be reporting soon on quarterly revenues; hopefully they show a further increase in sales.
"The loan constitutes an obligation of Curis Royalty, and is intended to be non-recourse to Curis. Under the terms of the loan, quarterly royalty payments received by Curis Royalty from Genentech will first be applied to pay (i) escrow fees payable by Curis pursuant to an escrow agreement between Curis, Curis Royalty, BioPharma-II and Boston Private Bank and Trust Company, (ii) Curis’ royalty obligations to academic institutions, (iii) certain expenses incurred by BioPharma-II in connection with the credit agreement and related transaction documents, including enforcement of its rights in the case of an event of default under the credit agreement and (iv) expenses incurred by Curis enforcing its right to indemnification under the collaboration agreement with Genentech. Remaining amounts, subject to caps of $2,000,000 per quarter in 2014 and $3,000,000 per quarter in 2015, will be applied first to pay interest and second, principal on the loan. Curis Royalty will be entitled to receive the remaining royalty amounts above the caps, if any, and Curis remains entitled to receive any contingent payments upon achievement of clinical development objectives. Curis Royalty retains its right to royalty payments related to sales of Erivedge following repayment of the loan."
$47 million in Cash and $30 Million Debt.
I would like very much if they keep the cash and reduce the interest rate.
Debt consolidation would cut costs by lowering their interest rate,
They also fail to mention how the 2017 note is going to be paid off EARLY! That is a really big deal. Now that Dan (the lawyer) is no longer CEO, I feel confident in Curis's potential and eventually PPS gain! GLTAL
Sentiment: Strong Buy
Shorts Hide the facts you neglected to mention royalty revenue :
Offsetting the decrease in license fee revenue, royalty revenues recognized from Genentech and Roche’s net sales of Erivedge increased $1,642,000 to $3,112,000 during the six months ended June 30, 2014 as compared to $1,470,000 during the same period in 2013, a 112% increase over the prior year period.
Since 2012, we achieved aggregate milestone payments totaling $27,000,000 under our collaboration with Genentech. In addition,
we received royalty revenues during 2012 in connection with Genentech’s net sales of Erivedge. Royalty revenues earned subsequent to December 2012 are being used to repay Curis Royalty’s outstanding principal and interest under the loan due to BioPharma-II
At the end of 2013 Erivedge revenues had not reduced the principal of $30,000,000 loan. "In December 2012, our wholly-owned subsidiary, Curis Royalty, received a $30,000,000 loan from BioPharma-II. In connection with the loan, we transferred to Curis Royalty our right to receive certain future royalty and royalty-related payments on the commercial sales of Erivedge that we may receive from Genentech.
The loan and accrued interest will be repaid by Curis Royalty using such royalty and royalty-related payments.
The loan constitutes an obligation of Curis Royalty, and is intended to be non-recourse to us. As of December 31,2013, Curis Royalty owed a total of $31,013,000, gross, to BioPharma-II comprised of principal and accrued interest."
Also it would be good to hear that Roche fired the IPF trial up again. In addition the trial- Ribavirin and Hedgehog Inhibitor With or Without Azacytidine in AML is expected to begin in the next month I believe.
No cheerleading, read their financials.
Aug 7. 10Q. The Company anticipates that existing cash, cash equivalents and investments at June 30, 2014 should enable it to maintain current and planned operations into 2016.
The Company recognized royalty revenues from Genentech’s net sales of Erivedge of $1,823,935 and $805,312 during the three months ended June 30, 2014 and 2013,
respectively, and $3,112,183 and $1,469,712 during the six months ended June 30, 2014 and 2013, respectively.
you fail to support your assertions with facts, not that I am bearish on Curis but your cheerleading does not help. Please explain how Curis has plenty of cash when its Erivedge royalties are still insufficient to cover the interest on Curis' loan from a hedgefund; true Erivedge received FDA approval in Feb, 2012 and yet its revenues have been appreciably below expectations, Curis has two pipleline drugs, CUDC 907 and 427, but they are still in phase one and the jury is still way out on whether FDA will approve them. I am hoping Curis will provide some positive developments over the next few months on the 907 front now that it has progressed to an expansion cohort
I remember one poster on the Yahoo board that loved PCYC
The stock traded for (I think) about $2
Looks like CRIS could fit his criteria
They have an FDA approved Cancer medication.
Plenty of Cash and a Good pipeline.
Time for someone to shake out the motives of our Board and CEO.